Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients

Gary C Yee, M. S. Kennedy, R. Storb, E. D. Thomas

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The effect of hepatic dysfunction, defined as abnormal serum bilirubin level, on oral cyclosporine (CSP) pharmacokinetics was examined in 28 marrow transplant patients who received CSP for prophylaxis of graft-v-host disease. Serum CSP concentrations were measured by radioimmunoassay. Forty-one concentration-time courses were studied, divided among patients with no (<1.2 mg/dL), mild (1.2 to 2.0 mg/dL), and moderate (2.0 to 5.0 mg/dL) hepatic dysfunction. CSP elimination, as determined by elimination rate constant and clearance, was delayed in patients with moderate hepatic dysfunction compared to those with no hepatic dysfunction (P <.05). The volume of distribution, lag time for absorption, maximum serum concentration, and time at which the maximum concentration was achieved was not affected by hepatic function. These data indicate that patients with moderate hepatic dysfunction have delayed CSP or CSP metabolite elimination and may be at higher risk for developing CSP-related toxicity.

Original languageEnglish (US)
Pages (from-to)1277-1279
Number of pages3
JournalBlood
Volume64
Issue number6
StatePublished - Dec 1 1984

Fingerprint

Transplants
Pharmacokinetics
Cyclosporine
Bone Marrow
Liver
Serum
Metabolites
Bilirubin
Grafts
Radioimmunoassay
Toxicity
Rate constants

ASJC Scopus subject areas

  • Hematology

Cite this

Yee, G. C., Kennedy, M. S., Storb, R., & Thomas, E. D. (1984). Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients. Blood, 64(6), 1277-1279.

Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients. / Yee, Gary C; Kennedy, M. S.; Storb, R.; Thomas, E. D.

In: Blood, Vol. 64, No. 6, 01.12.1984, p. 1277-1279.

Research output: Contribution to journalArticle

Yee, GC, Kennedy, MS, Storb, R & Thomas, ED 1984, 'Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients', Blood, vol. 64, no. 6, pp. 1277-1279.
Yee, Gary C ; Kennedy, M. S. ; Storb, R. ; Thomas, E. D. / Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients. In: Blood. 1984 ; Vol. 64, No. 6. pp. 1277-1279.
@article{694fdbe4bb81416fbe116e6f577f6542,
title = "Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients",
abstract = "The effect of hepatic dysfunction, defined as abnormal serum bilirubin level, on oral cyclosporine (CSP) pharmacokinetics was examined in 28 marrow transplant patients who received CSP for prophylaxis of graft-v-host disease. Serum CSP concentrations were measured by radioimmunoassay. Forty-one concentration-time courses were studied, divided among patients with no (<1.2 mg/dL), mild (1.2 to 2.0 mg/dL), and moderate (2.0 to 5.0 mg/dL) hepatic dysfunction. CSP elimination, as determined by elimination rate constant and clearance, was delayed in patients with moderate hepatic dysfunction compared to those with no hepatic dysfunction (P <.05). The volume of distribution, lag time for absorption, maximum serum concentration, and time at which the maximum concentration was achieved was not affected by hepatic function. These data indicate that patients with moderate hepatic dysfunction have delayed CSP or CSP metabolite elimination and may be at higher risk for developing CSP-related toxicity.",
author = "Yee, {Gary C} and Kennedy, {M. S.} and R. Storb and Thomas, {E. D.}",
year = "1984",
month = "12",
day = "1",
language = "English (US)",
volume = "64",
pages = "1277--1279",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients

AU - Yee, Gary C

AU - Kennedy, M. S.

AU - Storb, R.

AU - Thomas, E. D.

PY - 1984/12/1

Y1 - 1984/12/1

N2 - The effect of hepatic dysfunction, defined as abnormal serum bilirubin level, on oral cyclosporine (CSP) pharmacokinetics was examined in 28 marrow transplant patients who received CSP for prophylaxis of graft-v-host disease. Serum CSP concentrations were measured by radioimmunoassay. Forty-one concentration-time courses were studied, divided among patients with no (<1.2 mg/dL), mild (1.2 to 2.0 mg/dL), and moderate (2.0 to 5.0 mg/dL) hepatic dysfunction. CSP elimination, as determined by elimination rate constant and clearance, was delayed in patients with moderate hepatic dysfunction compared to those with no hepatic dysfunction (P <.05). The volume of distribution, lag time for absorption, maximum serum concentration, and time at which the maximum concentration was achieved was not affected by hepatic function. These data indicate that patients with moderate hepatic dysfunction have delayed CSP or CSP metabolite elimination and may be at higher risk for developing CSP-related toxicity.

AB - The effect of hepatic dysfunction, defined as abnormal serum bilirubin level, on oral cyclosporine (CSP) pharmacokinetics was examined in 28 marrow transplant patients who received CSP for prophylaxis of graft-v-host disease. Serum CSP concentrations were measured by radioimmunoassay. Forty-one concentration-time courses were studied, divided among patients with no (<1.2 mg/dL), mild (1.2 to 2.0 mg/dL), and moderate (2.0 to 5.0 mg/dL) hepatic dysfunction. CSP elimination, as determined by elimination rate constant and clearance, was delayed in patients with moderate hepatic dysfunction compared to those with no hepatic dysfunction (P <.05). The volume of distribution, lag time for absorption, maximum serum concentration, and time at which the maximum concentration was achieved was not affected by hepatic function. These data indicate that patients with moderate hepatic dysfunction have delayed CSP or CSP metabolite elimination and may be at higher risk for developing CSP-related toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0021684957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021684957&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 1277

EP - 1279

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -